共 108 条
[51]
Scolyer RA(2015)Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 372 2006-5524
[52]
van Essen TH(2019)Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study J Immuno Ther Cancer 7 299-2249
[53]
Machida YJ(2016)Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP) J Clin Oncol 34 9554-802
[54]
Augsburger JJ(2018)Combined effects of yttrium-90 transarterial radioembolization around immunotherapy for hepatic metastases from uveal melanoma: a preliminary retrospective case series J Vasc Interv Radiol 29 1369-1161
[55]
Correa ZM(2019)Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study Lancet Oncol 20 1083-2405
[56]
Shaikh AH(2018)Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors Nat Commun 9 1866-1239
[57]
Spagnolo F(2019)Evolutionary routes in metastatic uveal melanomas depend on MBD4 alterations Clin Cancer Res 25 5513-776
[58]
Buder K(2016)Identification of an Immunogenic subset of metastatic uveal melanoma Clin Cancer Res 22 2237-789
[59]
Rodriguez JMP(2017)Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study Lancet Oncol 18 792-830
[60]
Zimmer L(1998)High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma Br J Cancer 78 1156-1305